Dermendjian Mariette, Varma Swati, Krauss Alfred N, Auld Peter A M
Perinatology Center, Department of Pediatrics, New York Hospital-Cornell Medical Center, New York, New York 10021, USA.
Am J Perinatol. 2002 Apr;19(3):155-62. doi: 10.1055/s-2002-25314.
We tested the hypothesis that the initial functional residual capacity (FRC) of preterm infants with hyaline membrane disease (HMD) could predict the response to surfactant replacement (Survanta, 4 mL/kg/dose), with a better initial FRC being correlated with a greater improvement in PaO2, a/A PO2 ratio, and FRC. Thirty-four preterm infants were studied on 41 occasions. FRC and arterial blood gases were measured immediately prior to treatment. FRC was measured by the helium dilution method. Arterial blood gases were measured again after 30, 60, and 120 minutes. FRC was measured after 120 minutes. Twenty-seven treatments resulted in an increase in PaO2 >10 mmHg (responders); 14 did not (nonresponders). There was no correlation between initial FRC, change in FRC, and change in PaO2 (r2 = 0.07). These results suggest that there is no relationship between initial FRC and response to surfactant treatment.
我们检验了这样一个假设，即患有透明膜病（HMD）的早产儿的初始功能残气量（FRC）能够预测其对表面活性剂替代治疗（舒润坦，4 mL/kg/剂量）的反应，初始FRC越高，动脉血氧分压（PaO2）、肺泡-动脉血氧分压比值（a/A PO2）和FRC的改善就越大。对34例早产儿进行了41次研究。在治疗前即刻测量FRC和动脉血气。FRC采用氦稀释法测量。在30、60和120分钟后再次测量动脉血气。在120分钟后测量FRC。27次治疗使PaO2升高>10 mmHg（有反应者）；14次治疗未出现这种情况（无反应者）。初始FRC、FRC变化和PaO2变化之间无相关性（r2 = 0.07）。这些结果表明，初始FRC与表面活性剂治疗反应之间不存在关联。
